Tasquinimod improves radiographic PFS in mCRPC
(HealthDay)—For chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC), tasquinimod is associated with improved radiographic progression-free survival (rPFS), according to a phase III study ...
Jun 16, 2016
0
0